Raptiva Pregnancy Warnings
Healthcare providers are encouraged to enroll patients who become pregnant while taking efalizumab (or within six weeks of discontinuing the drug) in the Raptiva pregnancy registry.
Efalizumab has been assigned to pregnancy category C by the FDA. Animal studies have not been performed. There are no controlled data in human pregnancy. Efalizumab should only be given during pregnancy when need has been clearly established.
See references
